Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

Fineline Cube Mar 5, 2026
Company Deals

Rallybio to Acquire Candid Therapeutics in $700M+ Merger – Creates Leading Autoimmune T‑Cell Engager Company

Fineline Cube Mar 5, 2026
Company Deals

Edding Genor Expands ANGPTL3 siRNA Rights to Global – Restructures Napeptide Partnership

Fineline Cube Mar 4, 2026
Company Deals

Aidea Pharma Raises RMB 1.28B – $111M Allocated to Global HIV Integrase Inhibitor Development

Fineline Cube Mar 4, 2026
Company Deals

Star Sports Medicine Files Hong Kong IPO – Sports Medical Device Maker Targets Soft Tissue Injury Market

Fineline Cube Mar 4, 2026
Policy / Regulatory

China’s 2026 Government Work Report Unveils Healthcare Overhaul – VBP Optimization, TCM Innovation, and 300M Long‑Term Care Expansion

Fineline Cube Mar 5, 2026
Company Drug

HutchMed Initiates Phase I/IIa Trial for HMPL-A580 – Second Antibody-Targeted Triggered Conjugate Targets EGFR+ Solid Tumors

Fineline Cube Mar 5, 2026
Company Drug

AbbVie’s SKYRIZI Hits AFFIRM Study Endpoints in Crohn’s Disease – 55% Clinical Remission vs. 30% Placebo at Week 12

Fineline Cube Mar 5, 2026
Company Deals

Shanghai’s Matwings Secures Over $13.8 Million in Series A Financing for AI Protein Design

Fineline Cube Nov 18, 2024

Matwings, an AI-based protein design service provider headquartered in Shanghai, has announced the successful completion...

Company Drug

EMA’s CHMP Recommends Approval for MSD’s Keytruda Combo in Mesothelioma Treatment

Fineline Cube Nov 18, 2024

Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK), a leading US pharmaceutical company, has announced...

Company Drug

EMA’s CHMP Recommends Approval for BMS’s Opdivo/Yervoy Combo in mCRC

Fineline Cube Nov 18, 2024

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

Company Deals

Boston Scientific Expands Neuromodulation Portfolio with Axonics Acquisition

Fineline Cube Nov 18, 2024

Boston Scientific Corporation (NYSE: BSX), a leading player in the medical device industry, has announced...

Company Drug

Sandoz Receives EC Approval for Biosimilar to Eylea for Retinal Diseases

Fineline Cube Nov 18, 2024

Switzerland-based pharmaceutical company Sandoz (SWX: SDZ) has announced that it has received marketing approval from...

Company Medical Device

Peijia Medical Achieves First Compassionate Use of Taurus Trio TAVR System in Hong Kong

Fineline Cube Nov 18, 2024

Peijia Medical Ltd (HKG: 9996), a leading medical device company, has announced the completion of...

Company Drug

Sanofi’s Dupixent sBLA for Chronic Spontaneous Urticaria Accepted by FDA for Review

Fineline Cube Nov 18, 2024

French pharmaceutical giant Sanofi has announced that the US Food and Drug Administration (FDA) has...

Company Drug

Novo Nordisk Launches Semaglutide for Weight Management in China

Fineline Cube Nov 18, 2024

Denmark-based healthcare giant Novo Nordisk A/S (NYSE: NVO) has announced the official market launch of...

Company Drug

Sichuan Kelun-Biotech Secures NMPA Approval for Two Antibody Drug Conjugates

Fineline Cube Nov 18, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990), a leading biopharmaceutical company based in China, has...

Company Drug

Exegenesis Bio’s Gene Therapy EXG110 Earns Orphan Drug Status for Fabry Disease

Fineline Cube Nov 18, 2024

Exegenesis Bio, a leading provider of epigenetics experimental and analytical services headquartered in Hangzhou, has...

Company Deals

Shenzhen Weiguang Biological Partners with SUAT to Boost Life Science and Health Industry

Fineline Cube Nov 18, 2024

Shenzhen Weiguang Biological Products Co., Ltd. (SHE: 002880), a prominent blood products manufacturer in China,...

Company Drug

Janssen-Cilag’s Lazcluze-Rybrevant Combo Receives Positive EMA Opinion for NSCLC Treatment

Fineline Cube Nov 18, 2024

Janssen-Cilag International NV, a subsidiary of the US pharmaceutical giant Johnson & Johnson (J&J; NYSE:...

Company Drug

Shanghai Junshi Biosciences’ Toripalimab Wins UK Approval for Nasopharyngeal and Oesophageal Cancers

Fineline Cube Nov 18, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biopharmaceutical company based in...

Company Deals

C-Ray Therapeutics Secures Over $100 Million in Series A+ Financing for Radiopharmaceuticals

Fineline Cube Nov 18, 2024

C-Ray Therapeutics, a specialist in radiopharmaceuticals headquartered in Chengdu, has announced the successful completion of...

Company

BioNTech Acquires Biotheus for $800 Million, Enhancing Oncology Pipeline

Fineline Cube Nov 17, 2024

BioNTech (NASDAQ: BNTX), the biotech giant recognized for its role in developing the COVID-19 vaccine,...

Company

Suzhou Ribo Life Science Receives EU Approval for Phase II Trial of RBD5044

Fineline Cube Nov 16, 2024

Suzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals AB have announced that...

Company Drug

Ascentage Pharma Submits Application for Lisaftoclax, a Novel Oral Bcl-2 Inhibitor

Fineline Cube Nov 16, 2024

Ascentage Pharma (HKG: 6855) has announced that its proprietary oral Bcl-2 selective inhibitor, Lisaftoclax (APG-2575),...

Company

C-Ray Therapeutics Secures Over $100 Million in A+ Round Financing

Fineline Cube Nov 16, 2024

C-Ray Therapeutics (Chengdu) Co., Ltd., an innovative enterprise in the field of radioactive medicines, has...

Company Drug

Bliss Bio Secures NMPA Approval for BB-1712, Pioneering ADC Therapy

Fineline Cube Nov 16, 2024

Bliss Bio announced that its Investigational New Drug (IND) application for the innovative antibody-drug conjugate...

Company

Merck KGaA Reports 3.8% Organic Growth in Q3 2024 Financials

Fineline Cube Nov 15, 2024

Merck KGaA (NYSE: MRK), the German multinational science and technology company, has released its financial...

Posts pagination

1 … 230 231 232 … 631

Recent updates

  • HutchMed Initiates Phase I/IIa Trial for HMPL-A580 – Second Antibody-Targeted Triggered Conjugate Targets EGFR+ Solid Tumors
  • AbbVie’s SKYRIZI Hits AFFIRM Study Endpoints in Crohn’s Disease – 55% Clinical Remission vs. 30% Placebo at Week 12
  • China’s 2026 Government Work Report Unveils Healthcare Overhaul – VBP Optimization, TCM Innovation, and 300M Long‑Term Care Expansion
  • AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics
  • Ab&B Bio-Tech Wins FDA IND Approval for mRNA Mpox Vaccine – China’s First U.S.-Cleared Candidate Targets Immunocompromised Populations
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

HutchMed Initiates Phase I/IIa Trial for HMPL-A580 – Second Antibody-Targeted Triggered Conjugate Targets EGFR+ Solid Tumors

Company Drug

AbbVie’s SKYRIZI Hits AFFIRM Study Endpoints in Crohn’s Disease – 55% Clinical Remission vs. 30% Placebo at Week 12

Policy / Regulatory

China’s 2026 Government Work Report Unveils Healthcare Overhaul – VBP Optimization, TCM Innovation, and 300M Long‑Term Care Expansion

Company Deals

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.